Treatment of overactive bladder (OAB) with mirabegron 50 mg in the UK may result in lower healthcare resource utilization, lost productivity costs, and overall treatment costs compared with antimuscarinics.

Further work is needed to confirm these findings in different populations to assess the effects of mirabegron on the costs of treatment in other countries.